[{"id":"541c4dee-2db9-4752-89f8-12efa097adb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06521697","created_at":"2025-02-27T07:54:42.204Z","updated_at":"2025-02-27T07:54:42.204Z","phase":"Phase 4","brief_title":"Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery","source_id_and_acronym":"NCT06521697","lead_sponsor":"National Taiwan University Hospital","biomarkers":" KIM1","pipe":"","alterations":" ","tags":["KIM1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-26"},{"id":"beb52314-db86-4374-b877-6b02254ca840","acronym":"ICITOX","url":"https://clinicaltrials.gov/study/NCT04902846","created_at":"2021-05-26T15:53:08.436Z","updated_at":"2024-07-02T16:35:32.054Z","phase":"","brief_title":"Immune Checkpoint Inhibitors Nephrotoxicity","source_id_and_acronym":"NCT04902846 - ICITOX","lead_sponsor":"R. Laura Vicente Vicente","biomarkers":" KIM1 • LCN2","pipe":"","alterations":" ","tags":["KIM1 • LCN2"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 04/23/2024","primary_completion_date":" 04/23/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-10-24"},{"id":"95d0b020-45e1-46fb-b139-70c1335994d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05963334","created_at":"2023-07-27T17:08:59.436Z","updated_at":"2024-07-02T16:35:41.710Z","phase":"Phase 1/2","brief_title":"Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05963334","lead_sponsor":"Cairo University","biomarkers":" CEACAM5 • IL18 • KIM1 • LCN2","pipe":"","alterations":" ","tags":["CEACAM5 • IL18 • KIM1 • LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 11/30/2019","primary_completion_date":" 11/30/2019","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2023-07-27"},{"id":"f7825010-4c0f-4823-a337-62c43de4d013","acronym":"","url":"https://clinicaltrials.gov/study/NCT04755452","created_at":"2021-02-16T12:53:41.346Z","updated_at":"2024-07-02T16:35:45.259Z","phase":"","brief_title":"The Effect of Pneumoperitoneum (Raised Pressure in the Peritoneal Cavity) During Robotic Kidney/Prostate Cancer Surgery.","source_id_and_acronym":"NCT04755452","lead_sponsor":"Aalborg University Hospital","biomarkers":" VEGFA • KIM1 • CALB1 • CLU • LCN2","pipe":"","alterations":" ","tags":["VEGFA • KIM1 • CALB1 • CLU • LCN2"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/23/2020","start_date":" 12/23/2020","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2023-06-22"},{"id":"dd1c3097-3bf4-4d0a-a5ac-41a9ea67a30e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05640817","created_at":"2022-12-07T15:57:14.308Z","updated_at":"2024-07-02T16:35:59.553Z","phase":"","brief_title":"Nephroprotective Effect of Pentoxifylline Against Cisplatin in Patients With Head and Neck Cancer","source_id_and_acronym":"NCT05640817","lead_sponsor":"Tanta University","biomarkers":" KIM1","pipe":"","alterations":" ","tags":["KIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-12-07"},{"id":"afa19200-0e04-4b3b-b6e7-0140322be72a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05586009","created_at":"2022-10-19T13:56:28.212Z","updated_at":"2024-07-02T16:36:01.612Z","phase":"Phase 2","brief_title":"Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients","source_id_and_acronym":"NCT05586009","lead_sponsor":"Tanta University","biomarkers":" FASLG • KIM1","pipe":"","alterations":" ","tags":["FASLG • KIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 75","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-10-28"},{"id":"8bbfa7d0-55cc-4c62-8801-1cce0f1176d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04481672","created_at":"2021-01-18T21:31:06.987Z","updated_at":"2024-07-02T16:36:18.732Z","phase":"Phase 1","brief_title":"Intravenous Magnesium in Patients Receiving Cisplatin","source_id_and_acronym":"NCT04481672","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" KIM1","pipe":"","alterations":" ","tags":["KIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2022-01-11"},{"id":"407ac7e6-0c0a-45e1-bb71-0bd4c56bdc2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01848457","created_at":"2021-01-18T08:14:55.358Z","updated_at":"2024-07-02T16:36:48.338Z","phase":"Phase 2","brief_title":"Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","source_id_and_acronym":"NCT01848457","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" KIM1","pipe":"","alterations":" ","tags":["KIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xatmep (methotrexate oral solution) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 01/04/2016","primary_completion_date":" 01/04/2016","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2020-03-16"}]